Waters Corporation Shareholders Approve $17.5 Billion Merger with BD Biosciences, Transaction Set to Close February 2026
核心洞察
Waters Corporation (搜索) shareholders overwhelmingly approved the share issuance for the proposed $17.5 billion combination with Becton Dickinson's Biosciences and Diagnostic Solutions business, with approximately 99% of shares voting in favor.
The transaction has received all required regulatory approvals and a favorable IRS ruling, with the merger expected to close on February 9, 2026, subject to remaining customary closing conditions.
Analysts project significant financial benefits from the deal, estimating EPS accretion of approximately $0.10 in 2026 rising to $2.70 by 2028, with potential synergies of $345 million in total EBITDA by year five.
Waters Corporation (搜索) shareholders have delivered overwhelming support for the company's transformative $17.5 billion merger with Becton, Dickinson and Company's Biosciences and Diagnostic Solutions business, with approximately 99% of shares present voting in favor of the required stock issuance at a special shareholder meeting.
The transaction, first announced in July 2025, represents a significant consolidation in the life sciences tools and diagnostics sector. Waters has confirmed that all required regulatory approvals have been obtained, and BD (搜索) has received a favorable Private Letter Ruling from the Internal Revenue Service addressing federal income tax considerations. The merger is scheduled to close on February 9, 2026, pending satisfaction of remaining customary closing conditions.
Strategic Rationale and Financial Projections
William Blair (搜索) analysts, who initiated coverage on Waters with an Outperform rating, see substantial value creation potential from the combination. The firm estimates earnings per share accretion of approximately $0.10 in 2026, escalating to roughly $2.70 by 2028. Analyst Matt Larew projects $15.55 of EPS in 2027, rising to $17.18 once the BD (搜索) merger closes.
The analyst models roughly 20% upside by year-end 2026 based on a multiple of 26 times the 2027 post-merger EPS target. Waters currently trades at 26.7 times earnings, compared to its 10-year average of 25.9 times and peer group average of 25.2 times.
Waters holds a leading position in the resilient quality assurance and control market, with core end markets positioned to improve next year versus this year, marking the first year-over-year recovery since pre-COVID. The company's incremental growth catalysts are beginning to emerge as macro-driven recovery in tools continues.
Synergy Expectations and Market Precedents
The combined companies target $345 million in total EBITDA synergies by year five, though analysts believe this figure may prove conservative. William Blair (搜索) points to successful precedents in the life sciences sector, citing Thermo Fisher Scientific (搜索)'s acquisition of Life Technologies (搜索) and Merck (搜索)'s acquisition of Sigma-Aldrich (搜索), both of which realized greater post-acquisition synergies compared to pre-deal expectations.
The new Waters entity is expected to maintain above-group growth, margins, and return on invested capital. The portfolio addition creates strategic adjacencies and overlaps that analysts view as complementary to Waters' existing high-margin business model.
Market Response and Integration Considerations
Waters shares initially fell approximately 20% in the week following the BD (搜索) deal announcement, as investors expressed concerns about integration risk and the changed financial profile of adding a large, different business to Waters' otherwise simple, high-margin model. However, the stock has since rebounded as management clarified synergy targets and strategic fit through investor outreach.
Transaction Timeline and Next Steps
Following the shareholder approval, Waters has adjusted its fourth-quarter 2025 financial results release to coincide with the anticipated transaction close. The company will release results and host a conference call on Monday, February 9, 2026, at 8:30 a.m. Eastern Time, with a live webcast accessible through the Waters investor relations website.
"With this milestone complete, our focus is on closing the transaction and ushering in the next chapter of growth and innovation as a differentiated leader in life sciences and diagnostics," said Udit Batra, Ph.D., president and chief executive officer of Waters Corporation (搜索). "We look forward to creating meaningful value for patients, customers, employees, and shareholders alike."
The final vote results will be certified by inspectors of election and reported in a Form 8-K filing with the U.S. Securities and Exchange Commission. Waters shares were trading up 1.21% at $399.75 following the announcement.